Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

  1. Hecht, Markus ORCID logo
  2. Hahn, Dennis
  3. Wolber, Philipp
  4. Hautmann, Matthias G.
  5. Reichert, Dietmar
  6. Weniger, Steffi
  7. Belka, Claus
  8. Bergmann, Tobias
  9. Göhler, Thomas
  10. Welslau, Manfred
  11. Große-Thie, Christina
  12. Guntinas-Lichius, Orlando
  13. von der Grün, Jens
  14. Balermpas, Panagiotis
  15. Orlowski, Katrin
  16. Messinger, Diethelm
  17. Stenzel, Karsten G.
  18. Fietkau, Rainer

Download
s12885-020-07440-w.pdf 1,75MB
WeightNameValue
1000 Titel
  • Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
1000 Autor/in
  1. Hecht, Markus |
  2. Hahn, Dennis |
  3. Wolber, Philipp |
  4. Hautmann, Matthias G. |
  5. Reichert, Dietmar |
  6. Weniger, Steffi |
  7. Belka, Claus |
  8. Bergmann, Tobias |
  9. Göhler, Thomas |
  10. Welslau, Manfred |
  11. Große-Thie, Christina |
  12. Guntinas-Lichius, Orlando |
  13. von der Grün, Jens |
  14. Balermpas, Panagiotis |
  15. Orlowski, Katrin |
  16. Messinger, Diethelm |
  17. Stenzel, Karsten G. |
  18. Fietkau, Rainer |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-29
1000 Erschienen in
1000 Quellenangabe
  • 20(1):933
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-020-07440-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526421/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.!##!Methods!#!In this prospective, multi-center, non-interventional trial patients were treated either with platinum-based chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four weeks with a questionnaire containing ten visual analogue scales (VAS, range 0-100), which were summarized to the overall VAS score.!##!Results!#!Fourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at least the baseline and one subsequent questionnaire were available for analysis. Changes in the VAS score were rated as absolute differences from baseline. Negative values indicate improvement of symptoms. The overall VAS score improved significantly at the first post-baseline assessment in responders (- 2.13 vs. non-responders + 1.15, p = 0.048), and even more for the best post-baseline assessment (- 7.82 vs. non-responders - 1.97, p = 0.0005). The VAS for pain (- 16.37 vs. non-responders - 8.89, p = 0.001) and swallowing of solid food (- 16.67 vs. non-responders - 5.06, p = 0.002) improved significantly more in responders (best post-baseline assessment). In the multivariable Cox regression analysis, worse overall VAS scores were associated with worse overall survival (hazard ratio for death 1.12 per 10 points increment on the overall VAS scale, 95% CI 1.05-1.20, p = 0.0009).!##!Conclusion!#!In unselected patients beyond randomized controlled trials, treatment response lowers tumor symptom burden in recurrent and/or metastatic HNSCC.!##!Trial registration!#!ClinicalTrials.gov, NCT00122460 . Registered 22 Juli 2005.
1000 Sacherschließung
lokal Squamous Cell Carcinoma of Head and Neck/radiotherapy [MeSH]
lokal Aged [MeSH]
lokal Squamous Cell Carcinoma of Head and Neck/pathology [MeSH]
lokal Cetuximab/administration
lokal Progression-Free Survival [MeSH]
lokal Antibodies, Monoclonal, Humanized/administration
lokal Neoplasm Recurrence, Local/pathology [MeSH]
lokal Cisplatin/adverse effects [MeSH]
lokal Platinum/administration
lokal Proportional Hazards Models [MeSH]
lokal HNSCC
lokal Male [MeSH]
lokal Platinum/adverse effects [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Cetuximab/adverse effects [MeSH]
lokal Research Article
lokal Symptom
lokal Female [MeSH]
lokal Response
lokal Adult [MeSH]
lokal Cisplatin/administration
lokal Humans [MeSH]
lokal Neoplasm Metastasis [MeSH]
lokal Prospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Squamous Cell Carcinoma of Head and Neck/drug therapy [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/administration
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Medical and radiation oncology
lokal Disease-Free Survival [MeSH]
lokal Neoplasm Recurrence, Local/radiotherapy [MeSH]
lokal Cetuximab
lokal Chemotherapy
lokal Antibodies, Monoclonal, Humanized/adverse effects [MeSH]
lokal Neoplasm Recurrence, Local/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-2082-216X|https://frl.publisso.de/adhoc/uri/SGFobiwgRGVubmlz|https://frl.publisso.de/adhoc/uri/V29sYmVyLCBQaGlsaXBw|https://frl.publisso.de/adhoc/uri/SGF1dG1hbm4sIE1hdHRoaWFzIEcu|https://frl.publisso.de/adhoc/uri/UmVpY2hlcnQsIERpZXRtYXI=|https://frl.publisso.de/adhoc/uri/V2VuaWdlciwgU3RlZmZp|https://frl.publisso.de/adhoc/uri/QmVsa2EsIENsYXVz|https://frl.publisso.de/adhoc/uri/QmVyZ21hbm4sIFRvYmlhcw==|https://frl.publisso.de/adhoc/uri/R8O2aGxlciwgVGhvbWFz|https://frl.publisso.de/adhoc/uri/V2Vsc2xhdSwgTWFuZnJlZA==|https://frl.publisso.de/adhoc/uri/R3Jvw59lLVRoaWUsIENocmlzdGluYQ==|https://frl.publisso.de/adhoc/uri/R3VudGluYXMtTGljaGl1cywgT3JsYW5kbw==|https://frl.publisso.de/adhoc/uri/dm9uIGRlciBHcsO8biwgSmVucw==|https://frl.publisso.de/adhoc/uri/QmFsZXJtcGFzLCBQYW5hZ2lvdGlz|https://frl.publisso.de/adhoc/uri/T3Jsb3dza2ksIEthdHJpbg==|https://frl.publisso.de/adhoc/uri/TWVzc2luZ2VyLCBEaWV0aGVsbQ==|https://frl.publisso.de/adhoc/uri/U3RlbnplbCwgS2Fyc3RlbiBHLg==|https://frl.publisso.de/adhoc/uri/RmlldGthdSwgUmFpbmVy
1000 Hinweis
  • DeepGreen-ID: 489f11d28c12408aaba48afe7ceec57c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464609.rdf
1000 Erstellt am 2023-11-16T05:32:35.054+0100
1000 Erstellt von 322
1000 beschreibt frl:6464609
1000 Zuletzt bearbeitet Fri Dec 01 00:23:38 CET 2023
1000 Objekt bearb. Fri Dec 01 00:23:38 CET 2023
1000 Vgl. frl:6464609
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464609 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source